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A bstr"ct - A d inicldly plausible mathematical model is 
coostructed to describe the patbo-physiological dyoa mics or 
HIV-l induced AIDS during HAART therapy. The model 
equat ions incorporate phySiological interactions between 
non-inrected helper T cells, HIV-I inrected helper T cells, 
HIV-I virions in the blood plasma, HIV-! specific cytotoxic T 
cells and drug molecules or the HAART protocol. Investigative 
computer simulations arc perrormed to elucidate some 
therapeutic sceoarios such as viral annihilation and efficacious 
HAART therapy. In particular, some mathematical criter ia 
are derived for therapeutic outcomes such as viral persistence 
and viral annibilation. 
Kqworth: HAART therapy, computer simulations, 
mathemQtic,,/ modelilfg , HIV-l dYlfumics, AIDS cure c,iteri" 
1. INTRODUCTION 
In a previous publication [I I] , we presented a 
mathematical model describing the patho-physiological 
dynamics of the HIV-J virions during the asymptomat ic 
latency phase. As the HIV- I virions increase in the blood 
plasma, the number density of the CD4"" helper T cells 
decrease and the patient eventually develops AIDS. 
Currently, the most efficacious method for inducing a 
decline in number of HIV- I virions and effecting immune 
system reconstitution, is by using highly active antiretroviral 
therapy (HAART) [10, 15]. A typical HAART treatment 
protocol consists of combinations of protease inhibitors 
(Pis), and types of reverse transcriptase inhibitors (RTIs), 
which are fabricated as a compact matrix tablet [I , 2, 10]. It 
is clinically observed that the HAART treatment regimen 
has associated side effects such as gastro-intestinal toxicity, 
lipodystrophy, anemia, thrombocytopenia, and renal fai lure 
[3, 9, 10]. 
Several mathematical models have been developed to 
describe therapy ofHIV-J induced AIDS (4, 5, 12, 13l The 
authors Kirschner and Webb [4, 5] constructed models that 
described viral dynamics and drug resistance during 
monotherapy of HIV-I infection. Perelson et al.[12] 
described the decay characteristics of HIV- l infected 
compartments during combination therapy. In [15}, Ye, 
Kourtis and Kirschner constructed an elaborate 
mathematical model which described the reconstitution of 
thymic function in HIV-I patients during HAART therapy. 
Recent models, which involve optimal control therapies of 
HAART, include those by Stengel {14], Joshi [8], Adams et 
al. (I], Caetano and Yoneyama [2], and Joly (7]. 
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In this paper, an elaborate clinically plausible 
mathematical model is constructed to describe HAART 
therapy of HlV-I induced AIDS. This model incorporates 
constant continuous and periodic transdennal delivery, 
Michaelis-Menten drug absorption and clearance kinetics, 
and effects of viral latent reservoirs. Mathematical analyses 
of the model persistence are perfonned and viral persistence 
criteria are calculated. Investigative computer simulations 
are performed using hypothetical AIDS patients' 
physiological parameters. 
The major contribution of the current research is the 
fonnulation of robust criteria under which the HJV-I virions 
will persist or be annihi lated during the HAART drug 
therapy. 
II . PARAMETERS 
The model parameters, constants, and variables are 
listed as fo llows. 
X l: the number density of non-HIV -I-infected CD4- helper 
T-lymphocytes per unit volume 
X2: the number density of HIV- I infected CD4"" helper 
T -lymphocytes per unit volume 
Xl: the number density of HI V- I virions in the blood plasma 
per unit volume 
X4: the number density of HIV- I specific CDS- cytotoxic 
T-Iymphocytes per unit volume 
x~ : the concentration of drug molecules of the HAA RT 
treatment protocol 
Sl: rate of supply of un-infected CD4 + T4-lymphocytes 
$2: rate of supply of latently infected CD4 ~ T 4-lymphocytes 
$) : rate of supply of HIV-J virions from macrophage, 
monocytes, microglial cells and other lymphoid tissue 
different from T4-lymphocytes 
$4: rate of supply of CDS" Ta-1ymphocytes from the thymus 
D: rate ofHAART drug infusion by transdennal delivery 
a" b,: constant associated with acti vation of lymphocytes by 
cytokine interleukin-2 (IL-2) (i =1, 2, 3, 4) 
c: rate of HAART drug degradation and excretion 
11;: constant associated with HIV- l infection of CD4- T~ 
helper cells (i = 1, 2, 3) 
PI: the number of HIV -I virions produced per day by 
replication and budding in CD4" T4 helper cells 
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P2; rate constant associated with replication and "budding" 
of HIV-I in syncytia CD4+ T4 helper cells per day per 
microliter {j1I) and released into the blood plasma 
A the number of HIV-I virions produced per day by 
replication and "budding" in non-syncytia CD4+ T4 
helper cells and released into the blood plasma 
1}i: constant depicting the rate of which HIV-I virions 
incapacitate the CDS+ T g cytotoxic cells (i = I, 2) 
(O(h~):Michaelis-Menten metabolic rate constants 
associated with HAART drug elimination 
(o;,J;); Michaelis-Menten metabolic rate constants 
associated with HAART drug pharmacokinetics (i =2, 3) 
?: cytotoxic coefficient where 0 :5 ? :5 I (i = 2,3) 
q,: constant depicting competition between infected and 
un-infected CD4~ T4 helper cells (i = 1, 2) 
ki: constant depicting degradation, loss of clonogenicity or 
"death" (i = I, 2, 3, 4) 
e.o: constant depicting death or degradation or removal by 
apoptosis (programmed cell death) (i = 1, 2, 3, 4) 
K i : constant associated with the killing rate of infected CD4+ 
T. cells by CDS'" Tg cytotoxic lymphocytes (i = 1,2) 
All the parameters are positive. 
III . MODEL EQUA l!ONS AND ANALYSES 
The HIV- I patho-physiological dynamics during 
HAART therapy can be modeled using the following system 
of non-linear ordinary differential equations: 
· - s l~,;,x, k 
x 1 - l +a jx j e -al xjx l -Q l x l x 2- jxj-ejO 
· - s + ~b,.,+ k fI X z - 2 a 1x j x Ze a 1x jx l -Q2Xj X2 - zXz - jXl 
K ~2CJ"2X1X > - jXZX 4 -e10 - A2 + Xs 
Xl = S3 + P2XZX, + P 1X1 - a , x 1x1 -7J j X1X, - klXl - e10 
';JCJ"lX1XS 
A; + Xs 
· - s+ -b" "' K k x. - ~ a ~ xjx.e - 2XZX4 -1}2X1X , - .x. -eof{) 
i s = Df(l)- CJ" ox s _ CJ"2 X2X S _ C1" j XJ Xl 
..10 + xs A2 + xs AJ +xs 
{
I for constant continuous transdermal delivery 
f(t) = I sin n t I for periodic transdennal delivery 
x;(to)=x,o for i = {1, 2,3, 4,5} (3.1) 
The model includes the following clinical improvement: 
(i) The drug delivery uses transdermal, stealth-liposome 
encapsulated drug delivery, instead of the matrix tablet 
fonn because of improved therapeutic efficacy and 
reduced gastro-intestinal toxicity [6}. It is also assumed 
that elastic Iiposomes are fonnulated and selectively 
targeted such as to reduce toxicity to non-HIV - I-infected 
CD 4+ T cells (Xl) and CD S+ cytotoxic T cells (x. ). 
(ii) The HAART drug is such that each renal excretion and 
body clearance rate follows Michaelis-Menten kinetics. 
(iii) g(xj,x j ) = a J xjx je~b'~ 1 forj=o(1,2,4) 
This function depicts the process of lymphocyte 
activation which is mediated by Xl (CD 4) helper T cells. 
These cells secrete a lymphokine called interleukin-2. 
A. lnvariance of Non-Negativity of Solutions 
In this subsection, conditions will be derived under 
which solutions curves to the model initial values problem 
for HAART AIDS therapy will remain non-negative and 
bounded for all t e 9t+. 
Let to be the time at which the HAART therapy begins. 
Set 
C j = sup la ,xjx j e-b,x, J for j={1,2,4} 
leU, .r ] 
C J = sup [P2X2Xj + PlX1 ] 
1~[ lo. T I (3.2) 
here T is the time at which the HAAR T is discontinued. 
Also set 
5, = sup [ I 1 for i = {O,2.3} (3.3) 
' O[ t • . T I A, + X s 
The system of non-linear model equations exhibited in (3 . I) 
can be convened to the following system of differential 
inequalities using (3.2) and (3.3). LetAt) =0 1. 
i, < S , + C , - k 1 x t - e ,. 
i, < S, + C, - k 2 x 2 - e" 
x; < S ; + C; - k 1x J - e;o 
i, < S, + C , - k 4 x 4 - e 40 
Xs :5 D 5 Xi 
where 0 o Q+ 6 2 +6 , 
(3.4) 
x i (t O ) = x,Q where i = { I ,2,3,4,5} 
The Kamke comparison technique [II ] can be used to 
obtain the following system of non-linear inequalities. 
for i =0 {I ,2,34 } 
Xl :S ~ + y 1 e - 6 ' where 0 =0 0 0 + 0 1 + OJ (3 .5) 
and r, E R , '" ( 0, 00) and j = {1 ,2.3,4,5} 
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The preceding analyses lead to the following 
conclusions. 
Cl. The solutions to the HAART model are ultimately 
bounded. 
C2. The system is diss ipalive as implied by the inequalities 
. S +C-e hmsupx,(t)S; , ,, ' '0, i= II ,2,3,4} 
, 
C3. 
o lim sup x , (I):S 
Ii 
Therefore, we have the following theorem. 
; = {I,2,3,4} 
Theorem 1 There exists a TO>O such that for To < t <.,." all 
solutions to the HAART model equations (3.1) with initial 
values X.o E 9\ ' .. ={x,e 9\ I x,~, i=( I ,2,3,4,5)} will eventually 
enter the positive invariant region. 
A = {(X I' X l' X" X .. X, ) E 9\ ! 10 :s: x , < B,} 
where B , = sup X i 
'_I , • . TI 
In panicular, the solutions are trapped in the region A for all 
te9k 
B. Persistence of AIDS during HAART 
In this subsection, criteria will be derived under which 
the HIV·l virions will persist under HAAR T therapeutic 
protocols, with constant continuOus infusion with rate D. 
mi = inf {aixtxie· ·· ... } where i = {1,2,4} ~(' • • r) 
Lt = sup {alx) + q1x. + kl } 
"'(I • • r) 
L = sup{q x +k +K x + q2(12X2X~} 1 1 1 2 1'1 
"'I ... T) l"l + Xs 
V \ = sup {PIX) } 
.. ( .. . T) 
{ ,~,a, } L, = sup a )xI + 7]IX. +1\ ) +---
"[".T) ~ +X, 
m, = inf {PIX1X, + P,x,} 
.. ( .. . T) 
L. = inf {K1x 1 +17zXj +k. } 
"(<or) 
L _ in[ { (10 (12 X1 G"lXl } 
' - ... (>0.1") -\.+x, + A,;+x, + ~+xs 
Then the following differential inequalities are obtained: 
i l ;:: S I + m l - L\x l - elo 
i 2 ;:: S !+ m 2 -L!x2 -V t -e :!O 
i , ;:: S 3 + m , - L , X) - e JG 
X. ;:: s. + m. - L,x, - e oo 
x , ;::D - L, x , 
x , (t o) = X 'D where j = {I , 2,3,4,S } 
Therefore, the following inequalities are obtained: 
...... S I+ m l - e IO +d . " 
X I "" I e ' L, 
Xl;:: Sl+m l - U\-e:!O +dze- L " 
L, 
, S ! + m , '. + d le -L , I x, L , 
, S , + m, ,~ d . e- f." x , + L, 
The system will exhibit pers istence if 
lim inf X I ;:: S I + m1 - E' (O > 0 
L, 
lim inr Xl ~ SI + m 1 -V I -e zo > 0 
L, 
. S + m -e tnfx;:: l ! 30 >0 
, L, lim 
lim inr x. O!: S. + m. - eoo > 0 
L, 
lim inf x, O!: E... > 0 
L, 
(3.6) 
(3.7) 
(3.8) 
C. Necessary Criteria/or cure of AIDS during HAART 
One of the desired physiological steady states during 
HAART therapy is E- [ XI ' 0, 0, 0, Xs ]. In this 
configuration, the HIV·\ infected T4 helper cells (X2), and 
HIV-l virions (Xl ), and HIV·l specific cytotoxic Ta cells (X4) 
are annihilated by the HAART therapy . 
The necessary conditions for the cure of AIDS using 
constant continuous transdermal infusion HAART therapy 
include: 
S A1 _t,", l.. I +a1x l e - 1\ \ x 1 - E' IO 
S 2 -e%O =0 
S l -e lO = 0 
S. + a.x1x4e-
t
,I, - k4 x. - e 40 = 0 
(3.9) 
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The sufficient conditions for the cure of AIDS can be 
obtained using a Liapunov functional, to guarantee that 
E=[ XL ' 0, 0, O. XS J is globally asymptotically stable. This 
will be done in a future publ ication. 
exhibited in Table I and Table II. It should be stressed that 
the data values are estimates and some are from the literature 
values listed in [4, 5, II , 12]. Realistic parameters can only 
be obtained from actual AIDS patients under clinical 
conditions. Several investigative computer simulations are 
performed depicting the scenarios of viral persistence and 
viral annihilation . Two samples of the simulations are 
exhibited in Figure 1 for constant continuous transdermal 
infusion and Figure 2 for periodic transdermal infusion. 
IV . SIMULATION RESULTS AND DISCUSSION 
The computer simulations are performed using 
hypothetical AIDS patients' configuration ~ and E1, as 
TABLE I. Cm';STA>"l" COl'mNUOUS TRANSDER.MAL INFUSION PARAMETRlC CONFIGURATION f\. 
S, - 400 /daylpl SI-800/daylpl SJ-IOOO/day/pi S. '" 0.212 /dt.ylpl D - 1000 units 
0 1· 0.03/day/ceIUp/ Ol - 0.03/day/cell/pl A ~ 0.02Svi ronslC04·/daylpl Q, " 0.03/daylcelUpl q, - 50 mg/day 
b, - O. I/cclUpl bl - O.004/celUpl A = I .S vironslC04-Idt.y b. - O.Ollcc li/pI Oi '" 50.98 mglday 
a, - O.S/daylvirionlpl Ql- O.S/daylvi rionlpl a ) = 0.027 Iday/vi rionlpl Kl - 0.0024 Id ay/pl 0; = 10mg/day 
k, - O.OOOSfday/pl kl - O.OOS/day/pl kJ - 0.000 I/day k, - 0.OO8lday/pl Ao - S mglL 
q, - O.OOO4Sfday/.uf/ccll q, - O.OOOOllday/.uf/cell C;.o - O.OOOI/day e .... - 0.0002 ccllslday/pl A.l - s.s mglL 
e,o " 1.9 cells/day/pl fA - 1.5 virons/C04-'day '11- 0.25 m - 0.45 ~ .. 2.5 mglL 
X,O "" 200 cellslpl K, = O.OOOI/day/pl G - 0.8S XIo - 800 cells/pl x,. ~ 1000 ccllslpl 
e,. - 0.0005 ccllsldaylpl e. - O.OOI 
x,. - 400 cellslpl xJO-SOOcellslpl 
lOO X, ,'" X, '000 X, 
'" 
'''' 
800 
/ '''' 600 '''' lOO .'" 
" '''' 2'" \. 0 0 0 
0 2 l(",o~ lhs) , • 0 2 • I{ ..... alhs) , • 0 2 l{ ... .Jllhs) , • 
.00 X, '000 X, 
"'" .'" 
'" \ '00 . 00 200 200 \ l\ 0 0 
0 , • l{m""lI.s) 
, 
• 0 2 • l(",oalhs) 
, 
• 
Figure I. Simulation results using parametric configuration 1\ 
TABLE II. PERIODIC TllA.,."'-SOERMAL INFUSION P AM\{ETRlC COlo:FIGURA TlON P.t 
S, · 400 Iday/pl Sl "" 800 /day/ pi S, 10 /day/pi S, - IO/day/pi D - 1000 units 
01 "" 0.03/day/celVpl OJ " 0 .03/day/celUpl A - 0 .025 vironsIC04-/daylpl Q. = 0 .7S /day/cell/pl q, - 10 ",g/day 
b, "" O.Ol/cell1pl b, - O.OO4/celUpi /h - I. S virons/CD4·/dt.y b. - O.Ol/celUpI o;-tOO",glday 
(II - O.51dt.ylvi riCYf'llpl a%",0.5/daylvirionlpl a, - 0 .027/day/virionlpl Kl - 0.00024/daylpl q. - 10 mgJday 
k, - 0.OOO5/daylpl k, = O.OOS/day/pi k, " O.OOO l/day k, " O.OS/day/pl Ao~ S mgt! 
q, - O.OOO4S1day/.uf/cell q, .. O.OOOOI /dayl.uf/cell eJO· 0 .000 1 /day h. - 0.0002 ce lls/day/pl ).,- 10 mgtL 
e,o - 0.0025 cellslday/pi p. - 1.5 vironsICD4·/day '1, - 0.25 m - 0.45 A.,- 2.S nrglL 
XIO" 200 cel1s1p/ K,'" O.OOOlldaylpl .:, '" 0.85 -'#'" 750 cells/pi x,. '" 1500 celis/pi 
elO '" 0.0005 cells/day/pl $J ~ O.OOI ,-. 
X20 - 4OO cellslpl XJO - 500 cellslpl 
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Figure 2. Simulation results using parametric configuration ~ 
It is observed that, in principle, AIDS can be cured. In 
particular, using parametric configuration PI for constant 
continuous transdermal infusion, the HAART therapy was 
unsuccessful because the HIV -I vIrIons increased 
dramatically during the therapy, whereas the CD4+ helper T 
cells were eliminated. In Figure 2, using periodic 
transdermal infusion with parametric configuration P2, it is 
observed that the HAAR T therapy was successful because the 
HIV-J virions were annihilated, whereas the CD4"' helper T 
cells and the CDS+ HIV - 1 specific cytotoxic T cells 
repopulated. 
It should be mentioned that there are other simulation 
scenarios in which the constant continuous transdennal 
infusion were successful and the periodic transdennal 
infusion were unsuccessful. Those scenarios will be presented 
in a future paper. 
V. SUMMARIZING REMARKS 
In this paper, a clinically plausible mathematical model 
for HAART therapy is presented which incorporates the 
patho-physiological dynamics of HIV- l virions. The novel 
transdennal route of drug delivery which minimizes drug 
toxicity is utilized. The simulations ofthe model show that for 
some given AIDS patients' parametric configurations, it is 
possible to cure AIDS. The necessary mathematical criteria 
for these scenarios have been presented in the paper. The next 
step in the research towards the cure for AIDS is to 
investigate whether these results can be achieved in vivo as 
well as in the human AIDS patients. 
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